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SHORT COMMUNICATION
Papillary and follicular thyroid carcinomas show a different pattern of
ras oncogene mutation
P.A. Wright', N.R. Lemoine'*, E.S. Mayall', F.S. Wyllie', D. Hughes2, E.D. Williams' &
D. Wynford-Thomas'
'CRC Thyroid Tumour Biology Research Group, Department ofPathology, University of Wales College ofMedicine, Heath Park,
CardifCF4 4XN, UK; and 2LRF Preleukaemia Unit, Department ofHaematology, University of Wales College ofMedicine,
CardifCF4 4XN, UK.
In a small initial study of oncogene activation in differen-
tiated thyroid cancer, using DNA transfection and tumor-
igenicity assays, we identified activating ras mutations in
80% (4/5) of follicular carcinomas, but in only 20% (2/10) of
papillary carcinomas (Lemoine et al., 1988). However, Suarez
et al. (1988), using the 'focus' transformation assay, reported
two out of a total of three papillary carcinomas to have
activated ras oncogenes, while Fusco et al. (1987), also using
DNA transfection techniques, failed to find any activating
ras mutations in 20 papillary cases analysed. These con-
flicting results indicated the need for further study of the
prevalence of ras mutations in thyroid cancer.
We now report a further series of papillary carcinomas,
analysed by polymerase chain reaction (PCR) amplification
and oligonucleotide probing of archival material, and sum-
marise our data on the incidence and type of mutation in a
total of 33 differentiated thyroid carcinomas.
Wax-embedded tissue blocks of eight papillary thyroid
carcinomas (up to 7 years old) were obtained from the
archives of the Department of Pathology, University of
Wales College of Medicine. Sections of 5.m were
deparaffinised twice with xylene, washed twice with ethanol
and vacuum desiccated (Shibata et al., 1988). Dried pellets
were mixed with sterile water, denatured for 10 min at 95°C
and rapidly cooled to 4'C. PCR incubations were prepared
with a Perkin Elmer/Cetus Gene Amp kit according to the
manufacturers' protocol. Final concentrations were 10 mM
Tris pH 8.3, 50 mM KCI, 1.5 mM MgCl2, 0.2 mM of each
dNTP, 1 tIM of each of a pair of amplimers and 2.5 units of
Taq DNA polymerase (Saiki et al., 1986). Amplimers were 20
bases long, each pair enclosing an amplified region of 100 bp.
Samples received 50 cycles of amplification in a Cetus ther-
mal cycler, with 1 min denaturation at 94°C, 2.5 min anneal-
ing at 55'C and 3 min extension at 72°C. A 10pl aliquot of
each incubation was run on a 2.5% agarose gel to check for
specific amplification, and reactions were repeated until sharp
single bands were obtained.
After an initial quantitation, 5-12gdl of each PCR-amp-
lified mixture was diluted to 200 tlI in 1OmM Tris pH 8.0/
1 mM EDTA, denatured at 95°C for 5 min and cooled
rapidly to 4'C. Replicate slotblots, prepared using Hybond-N
filters (Amersham) and a Millipore vacuum slotblot
apparatus were prehybridised at 56°C for 30 min in 3 M
tetramethylammonium chloride (TEMAC)/50 mM Tris
pH 7.5/2 mM EDTA/0.3% SDS/5 x Denhardts solution,
100 flg ml-' denatured herring sperm DNA (Wood et al.,
1985). Filters were hybridised for 1-2 h at 56°C with 32P-end-
labelled 20mer oligonucleotide probes specific for mutations
altering aminoacids at the 12, 13, and 61 positions of each of
the three human ras genes. As a check on quantitation, filters
were first autoradiographed after non-stringent washes in
2 x SSPE/0.1% SDS at room temperature. They were then
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washed in 3 M TEMAC/50 mM Tris pH 7.5/2 mM EDTA/
0.3% SDS at 59°C for 10 min followed by high stringency
washes in 5 x SSPE/0.1% SDS for 10 min at a range of
higher temperatures, depending on probe sequence (H12,
74°C; H61, 68°C; K12/13, 64°C; K61, 61°C; N12/13, 64°C;
N61, 59°C).
Two of the 8 papillary cancers showed a point mutation in
a potentially activating region of a ras oncogene. A C-*A
transversion at position I of codon 61 of H-ras, giving a
glutamine-*lysine substitution, was observed in case 4 (Fig-
ure 1). Case 7 showed an A-*C transversion at position 2 of
codon 61 of the K-ras gene giving a glutamine+proline
substitution (Figure 2). (For case 4, non-tumour tissue was
also assayed; it did not contain the mutation).
When these results are combined with our previous series
of papillary carcinomas, this gives a total of three mutations
out of 17 cases tested. (One previous case, in which ionising
radiation was the probable aetiological agent, has been ex-
cluded since studies in progress indicate that radiation
exposure significantly influences the incidence of ras mutation
in these tumours.) Since the other previously reported muta-
tion (Lemoine et al., 1988) was K-ras 13, glycine-*aspartate,
all three mutations detected in papillary cancers have been
different. In contrast, the combined total for our two series
of follicular cancers (Lemoine et al., 1988, 1989) was eight
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Figure I Oligonucleotide hybridisation analysis of eight cases of
papillary carcinoma using sequence-specific probes for the H-ras
oncogene. Case 4 shows hybridisation to the mutant probe comp-
lementary to the sequence coding for lysine at codon 61 (H-61
lys) as well as to the normal probe (H-61 wt) containing the
sequence for glutamine at codon 61 thus demonstrating the
presence of both wild-type and mutant alleles in this tumour
DNA. N = normal control DNA. (Final high stringency washes
carried out at 74°C.)
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Figure 2 Oligonucleotide hybridisation of same cases as in Fig-
ure I using probes for the K-ras oncogene. Case 7 shows hyb-
ridisation to the mutant-specific probe for K-61 proline as well as
to the probe for the normal sequence (glutamine), K-61 wt,
demonstrating the presence of both wild-type and mutant alleles.
(Final high stringency washes carried out at 62°C.)
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mutations out of 15 cases tested, with four of these having
the same H61 glutamine-*arginine substitution, and one hav-
ing an N61 glutamine-*arginine substitution. (The remainder
were H12 glycine-*aspartate, K12 glycine-*serine, and N61
glutamine-*leucine.)
Several points arise from this new data. First, as far as we
are aware, this is the first report of a K61 proline mutation
in a human cancer. Secondly, we have now confirmed in a
larger series that the overall rate of ras mutation in papillary
carcinomas (3/17; 17%) is significantly lower than in fol-
licular carcinomas (8/15; 53%), (X2= 4.95; P<0.05). Thir-
dly, none of the 17 papillary cases had a position 61 glut-
amine-*arginine substitution, compared to five out of 15
follicular cancers.
We have therefore identified a statistically significant
(though not absolute) distinction in the prevalence of a
specific oncogene mutation in two types of carcinoma arising
from the same cell of origin, the thyroid follicular cell. It
would seem likely that this difference in ras oncogene activa-
tion is related to the known differences in epidemiology,
pathology and clinical behaviour of the two cancers.
One important difference lies in their metastatic potential.
Follicular carcinomas disseminate widely in the bloodstream,
whereas papillary carcinomas spread locally via lymphatics
(Frazell & Foote, 1958). Experimental transformation of
non-tumorigenic rodent fibroblast lines with an activated
Ha-ras gene has been shown to confer ability to metastasise
via the bloodstream (Muschel et al., 1985) and to increase
production and secretion of proteases such as cathepsin L
which are likely to contribute to this process (Denhardt et
al., 1987). However, our data do not suggest that ras is an
absolute and sole determinant of metastatic potential in
thyroid tumour cells, since a significant minority (17%) of
papillary carcinomas do have a potentially activating ras
mutation.
An alternative explanation for the different pattern of ras
mutation is suggested by our study of thyroid adenomas
(Lemoine et al., 1989), which showed that the prevalence of
ras mutation is as high in micro-follicular adenomas as in
follicular carcinomas. There is evidence that follicular car-
cinomas arise from pre-existing adenomas, whereas papillary
carcinomas classically arise de novo (De Groot et al., 1984).
Thus the higher rate of ras mutation in follicular carcinomas
may simply reflect their origin from adenomas, in which ras
activation presumably plays a key early role, and may not be
related directly to the differences in behaviour of the cancers.
It is not clear whether the subset of papillary cancers
which do contain a mutant ras gene show any difference in
biological behaviour, e.g. increased metastatic potential or a
worse prognosis, compared to the majority. In our series
there was no detectable correlation with any clinical or his-
topathological features but clearly a much larger, prospective
study will be needed to establish this with certainty.
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